--- title: "Grifols (GRF) stock listing, news and investor profile" url: "https://aibio.space/companies/grifols-s-a/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Grifols, S.A. (BME: GRF), Spain. The directory classifies it as Pharmaceuticals: Major. Listing facts, related biotech companies and news on aibio.space." --- GRF Grifols, S.A. BME · Spain # Grifols (GRF) news Debt Financing · 2026-07-28 ## [Grifols refinances all 2027 maturities with about €3 billion term loan](https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/) Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. ## Latest Grifols news We have not published a story on Grifols yet. When there is news, it will appear here. ## Grifols at a glance - **Ticker**: GRF - **Listing**: BME - **Country**: Spain ### Related companies - [Labiana Health SA](https://aibio.space/companies/labiana-health/) BME: LAB - [Faes Farma](https://aibio.space/companies/faes-farma-s-a/) BME: FAE - [LABORATORIO REIG JOFRE](https://aibio.space/companies/laboratorio-reig-jofre-s-a/) BME: RJF - [Almirall SA](https://aibio.space/companies/almirall/) BME: ALM - [Laboratorios Farmaceuticos Rovi](https://aibio.space/companies/laboratorios-farmaceuticos-rovi-s-a/) BME: ROVI - [Vytrus Biotech SA](https://aibio.space/companies/vytrus-biotech/) BME: VYT - [Pharma Mar SA](https://aibio.space/companies/pharma-mar/) BME: PHM - [Biotechnology Assets SA](https://aibio.space/companies/biotechnology-assets/) BME: BST ### Also on BME - [Almirall SA](https://aibio.space/companies/almirall/) ALM - [Labiana Health SA](https://aibio.space/companies/labiana-health/) LAB - [Laboratorios Farmaceuticos Rovi](https://aibio.space/companies/laboratorios-farmaceuticos-rovi-s-a/) ROVI - [Faes Farma](https://aibio.space/companies/faes-farma-s-a/) FAE - [Vytrus Biotech SA](https://aibio.space/companies/vytrus-biotech/) VYT - [LABORATORIO REIG JOFRE](https://aibio.space/companies/laboratorio-reig-jofre-s-a/) RJF ## What Grifols does Grifols, S.A. is a vertically integrated global producer of plasma derivatives, and the company says it ranks among the three largest producers in the industry by total sales. Its activities include sourcing raw material through a plasma collection network of more than 400 operating centers in the United States, Germany, Austria, the Czech Republic, Hungary, Canada and Egypt, manufacturing plasma derivative products, and selling them to healthcare providers. The company also researches, develops, manufactures and markets in vitro diagnostics products, including analytical instruments, reagents and software for clinical and blood bank laboratories, along with hospital products. Among its recent milestones, the European Medicines Agency certified the entire value chain of Grifols Egypt in December 2025, and the company acquired 28 plasma collection centers in the United States from ImmunoTek in February 2025. Its San Diego plant began manufacturing Grifols DG Gel card and reagent red blood cells, used for blood typing, in October 2025. Through its acquisition of Biotest Holdings, Grifols has increased its shareholding in the German company Biotest, which supplies plasma protein products and biotherapeutic drugs, to 100.0% of ordinary voting shares. | Product or program | What it is | Stage | |---|---|---| | Plasma-derived medicines | Plasma derivative products, including immunoglobulins, albumin and coagulation factors | | | Grifols DG Gel card and reagent red blood cells | Blood typing products used to ensure transfusion compatibility | manufacturing started October 2025 at San Diego plant | | In vitro diagnostics products | Analytical instruments, reagents and software for clinical and blood bank laboratories | | Summarised from the company's [20-F filed Apr 17, 2026](https://www.sec.gov/Archives/edgar/data/1438569/000110465926044901/grfs-20251231x20f.htm). ## Questions about Grifols What is the ticker symbol of Grifols? Grifols, S.A. trades under the ticker GRF on BME. Where is Grifols listed? Grifols, S.A. is listed on BME. Our directory also records these other listings: BME:GRF.P; DUS:OZTA; EUROTLX:4GRF; FWB:OZTA; GETTEX:G0F0; GETTEX:OZTA; HAM:OZTA; HAN:OZTA; LS:A2ABUQ; LSIN:0RDU; LSIN:0RDV; LSX:A2ABUQ; LSX:A2ABZN; MUN:OZTA; NASDAQ:GRFS; OTC:GIFLF; OTC:GIFOF; SWB:OZTA; TRADEGATE:OZTA; VIE:GRF; XETR:OZTA. What is the SEC CIK of Grifols? The SEC Central Index Key (CIK) for Grifols, S.A. is 1438569. Its filings are on SEC EDGAR. Which country or territory is Grifols listed under? Our directory records Grifols, S.A. under Spain. What does Grifols do? Our directory classifies Grifols, S.A. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Grifols? The ISIN recorded for Grifols, S.A. is ES0171996087. Does aibio.space cover Grifols? aibio.space lists Grifols, S.A. among 2,820 public biotech companies and publishes its news here as stories appear. What does Grifols develop? Grifols, S.A. is a vertically integrated global producer of plasma derivatives, and the company says it ranks among the three largest producers in the industry by total sales. Its activities include sourcing raw material through a plasma collection network of more than 400 operating centers in the United States, Germany, Austria, the Czech Republic, Hungary, Canada and Egypt, manufacturing plasma derivative products, and selling them to healthcare providers. What is Plasma-derived medicines from Grifols? Plasma-derived medicines: Plasma derivative products, including immunoglobulins, albumin and coagulation factors What is Grifols DG Gel card and reagent red blood cells from Grifols? Grifols DG Gel card and reagent red blood cells: Blood typing products used to ensure transfusion compatibility Stage: manufacturing started October 2025 at San Diego plant. What is the latest Grifols (GRF) stock news? Our latest story on Grifols, dated Jul 28, 2026: "Grifols refinances all 2027 maturities with about €3 billion term loan". Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. [Source](https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/). Does Grifols have debt, a term loan or convertible notes? Our latest debt story, dated Jul 28, 2026: "Grifols refinances all 2027 maturities with about €3 billion term loan". Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. [Source](https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/). Is Grifols a smaller reporting company? SEC records list Grifols, S.A.'s filer category as: Large accelerated filer. Where is Grifols headquartered? SEC records list its business address as 1585 BROADWAY, NEW YORK, NY, 10036. What did Grifols last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-07-30. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465926088529/tm2621687d1_6k.htm). ## Investor discussion: Grifols Members talk about Grifols (GRF). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Grifols, newest first. Each line links the filing it comes from. 1. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465926062230/tm2614775d1_6k.htm) 2. 2025-07-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465925071915/tm2521924d2_6k.htm) 3. 2025-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465925058641/tm2517815d1_6k.htm) 4. 2025-05-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465925044928/tm2514176d1_6k.htm) 5. 2025-03-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465925029805/tm2510933d1_6k.htm) 6. 2024-12-23 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465924131050/tm2431865d1_6k.htm) 7. 2024-12-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1438569/000110465924127574/tm2430789d1_6k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open BME:GRF on TradingView](https://www.tradingview.com/symbols/BME-GRF/). ## SEC filings and registration - **SEC name**: Grifols SA - **CIK**: 1438569 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: GRFS (Nasdaq), GIFLF (OTC), GIFOF (OTC), GIKLY (OTC) - **Filer category**: Large accelerated filer - **Business address**: 1585 BROADWAY, NEW YORK, NY, 10036 - **Phone**: 212-969-3335 ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926088529/tm2621687d1_6k.htm) filed 2026-07-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926087634/tm2621481d1_6k.htm) filed 2026-07-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926076294/tm2618474d1_6k.htm) filed 2026-06-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926075705/tm2618302d1_6k.htm) filed 2026-06-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926062230/tm2614775d1_6k.htm) filed 2026-05-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926056966/tm2613942d1_6k.htm) filed 2026-05-07 - [20-F](https://www.sec.gov/Archives/edgar/data/1438569/000110465926044901/grfs-20251231x20f.htm) filed 2026-04-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1438569/000110465926043217/tm2611793d1_6k.htm) filed 2026-04-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001438569), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Grifols, S.A. is a public biotech or pharmaceutical company listed on BME under the ticker GRF, recorded under Spain. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Grifols, S.A. - **Ticker**: GRF - **Listing**: BME - **Country or territory**: Spain - **Business scope**: Pharmaceuticals: Major - **ISIN**: ES0171996087 - **Other listed symbols**: BME:GRF.P; DUS:OZTA; EUROTLX:4GRF; FWB:OZTA; GETTEX:G0F0; GETTEX:OZTA; HAM:OZTA; HAN:OZTA; LS:A2ABUQ; LSIN:0RDU; LSIN:0RDV; LSX:A2ABUQ; LSX:A2ABZN; MUN:OZTA; NASDAQ:GRFS; OTC:GIFLF; OTC:GIFOF; SWB:OZTA; TRADEGATE:OZTA; VIE:GRF; XETR:OZTA - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/BME-GRF/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/grifols-s-a/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Grifols (GRF) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/grifols-s-a/